Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...
The decision to recall approximately three million sensors follows reports of potentially life-threatening errors in the devices. The malfunction causes the sensors to deliver incorrect low glucose ...
The Food and Drug Administration has issued an alert concerning two glucose monitors with a “high-risk” sensor issue. Abbott Diabetes Care initiated a “medical device correction” on Nov. 24, for ...
Abbott Laboratories ABT recently made its FreeStyle Libre 3 Plus sensor available to Canadians living with diabetes. This latest generation glucose monitoring device features the world's smallest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback